Literature DB >> 29296831

TG02 inhibits proteasome inhibitor-induced HSF1 serine 326 phosphorylation and heat shock response in multiple myeloma.

Shardule P Shah1, Ajay K Nooka1, Sagar Lonial1, Lawrence H Boise1.   

Abstract

Proteasome inhibition activates multiple kinases in myeloma cells resulting in the phosphorylation of p53, HSP27, c-JUN, and HSF1.TG02 inhibits proteasome inhibitor (PI)-induced HSF1 pS326, representing a novel mechanism for a TG02 and PI combination.

Entities:  

Year:  2017        PMID： 29296831      PMCID： PMC5728095          DOI： 10.1182/bloodadvances.2017006122

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


  13 in total

1.  Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma.

Authors:  Katelyn G Ponder; Shannon M Matulis; Sadae Hitosugi; Vikas A Gupta; Cathy Sharp; Francis Burrows; Ajay K Nooka; Jonathan L Kaufman; Sagar Lonial; Lawrence H Boise
Journal:  Cancer Biol Ther       Date:  2016-07-02       Impact factor: 4.742

2.  TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties.

Authors:  K C Goh; V Novotny-Diermayr; S Hart; L C Ong; Y K Loh; A Cheong; Y C Tan; C Hu; R Jayaraman; A D William; E T Sun; B W Dymock; K H Ong; K Ethirajulu; F Burrows; J M Wood
Journal:  Leukemia       Date:  2011-08-23       Impact factor: 11.528

3.  The multi-kinase inhibitor TG02 overcomes signalling activation by survival factors to deplete MCL1 and XIAP and induce cell death in primary acute myeloid leukaemia cells.

Authors:  Monica Pallis; Amina Abdul-Aziz; Francis Burrows; Claire Seedhouse; Martin Grundy; Nigel Russell
Journal:  Br J Haematol       Date:  2012-08-30       Impact factor: 6.998

4.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

Review 5.  When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response.

Authors:  Shardule P Shah; Sagar Lonial; Lawrence H Boise
Journal:  Mol Cancer Res       Date:  2015-05-26       Impact factor: 5.852

6.  Potent antimyeloma activity of a novel ERK5/CDK inhibitor.

Authors:  Stela Álvarez-Fernández; María Jesús Ortiz-Ruiz; Tracy Parrott; Sara Zaknoen; Enrique M Ocio; Jesús San Miguel; Francis J Burrows; Azucena Esparís-Ogando; Atanasio Pandiella
Journal:  Clin Cancer Res       Date:  2013-03-26       Impact factor: 12.531

Review 7.  The Tao of myeloma.

Authors:  Lawrence H Boise; Jonathan L Kaufman; Nizar J Bahlis; Sagar Lonial; Kelvin P Lee
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113

8.  Molecular sequelae of proteasome inhibition in human multiple myeloma cells.

Authors:  Nicholas Mitsiades; Constantine S Mitsiades; Vassiliki Poulaki; Dharminder Chauhan; Galinos Fanourakis; Xuesong Gu; Charles Bailey; Marie Joseph; Towia A Libermann; Steven P Treon; Nikhil C Munshi; Paul G Richardson; Teru Hideshima; Kenneth C Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-21       Impact factor: 11.205

9.  KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models.

Authors:  Irene Riz; Teresa S Hawley; Robert G Hawley
Journal:  Oncotarget       Date:  2015-06-20

10.  The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells.

Authors:  Mohamed-Amine Hamouda; Nathalie Belhacene; Alexandre Puissant; Pascal Colosetti; Guillaume Robert; Arnaud Jacquel; Bernard Mari; Patrick Auberger; Frederic Luciano
Journal:  Oncotarget       Date:  2014-08-15
View more
  1 in total

1.  Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report.

Authors:  Fieke W Hoff; Anneke D van Dijk; Yihua Qiu; Peter P Ruvolo; Robert B Gerbing; Amanda R Leonti; Gaye N Jenkins; Alan S Gamis; Richard Aplenc; E Anders Kolb; Todd A Alonzo; Soheil Meshinchi; Eveline S J M de Bont; Sophia W M Bruggeman; Steven M Kornblau; Terzah M Horton
Journal:  Blood       Date:  2021-02-25       Impact factor: 22.113
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.